Prostate Cancer Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies
With over 900 key pharmaceutical companies working, the Prostate cancer pipeline projects a robust and promising picture in near future, says DelveInsight
DelveInsight’s ‘Prostate Cancer Pipeline Insights’ report highlights major breakthroughs happening in the domain, emerging therapies in different stages of clinical development, segmented based on MoA, RoA, molecule types, drug delivery platform, and so on.
Some of the key highlights from the Prostate Cancer Drug Pipeline report:
- The present Prostate cancer treatment comprises surgery, radiation therapy, and proton beam therapy. Chemotherapy, hormonal therapy, cryosurgery, and high-intensity focused ultrasound (HIFU) are also among the prescribed treatment strategies.
- Out of all the emerging Prostate cancer drugs, SHR3860, Cabozantinib, Aglatimagene besadenovec, LY01005, [18F]PSMA-1007, HC-1119, VERU-111, and ARV 110 are expected to enter the market in the next decade.
- Key companies dedicated to advance the Prostate cancer drug pipeline are Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candle Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune, CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics, and several others.
- Novel Prostate cancer pipeline products include P PSMA 101, Autologous adipose-derived mesenchymal stem cell therapy, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, VERU-100.
- Vaccitech is currently developing the ChAdOx1-MVA 5T4 vaccine (VTP-008). This vaccine will be used in combination with the immunotherapy drug called nivolumab which is an anti-PD-1 (Programmed Death protein-1) monoclonal antibody.
- Ultimovacs has started the clinical evaluation of Novel TET Tetanus-Epitope Targeting (TET)-platform-based TENDU Vaccine for the treatment of Prostate cancer.
- In October 2020, Foresee Pharmaceuticals announced that 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the U.S. Food and Drug Administration (FDA).
- Takeda has granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries). U.S Food and Drug Administration approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist Relugolix on December 18, 2020, for the treatment of adult patients with advanced prostate cancer.
Prostate cancer originates from the prostate gland located in the pelvis, next to the bladder, of men. It is the second-leading cause of death due to cancers in men in the U.S. About 1 in 9 men are diagnosed with prostate cancer in their lifetime. Growths in the prostate can be benign (not cancer) or malignant (cancer).
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Globenewswire